Market Overview

Novocure to Present at Two Upcoming Investor Conferences


Novocure (NASDAQ:NVCR) announced today that it will participate in two
upcoming investor conferences.

Wilco Groenhuysen, Novocure's Chief Financial Officer, will participate
in the 2018 Wedbush PacGrow Healthcare Conference on Aug. 15, 2018, in
New York City. Mr. Groenhuysen's presentation will begin at 12:45 p.m.

Additionally, William Doyle, Novocure's Executive Chairman, will
participate in the Wells Fargo 2018 Healthcare Conference on Sept. 6,
2018, in Boston. Mr. Doyle's presentation will begin at 1:55 p.m. EDT.

Live audio webcasts of the presentations can be accessed from the
Investor Relations page of Novocure's website,,
and will be available for replay for at least 14 days following the

About Novocure

Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure's commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit
or follow us at

View Comments and Join the Discussion!